期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺癌转移的血管生成途径研究 被引量：4

在线阅读 下载PDF
导出
摘要 肺癌是一种常见的恶性肿瘤,发展迅速,严重威胁人类的身体健康,是导致癌症患者死亡的主要原因之一。每年大约有160万肺癌新发病例和140万人死于肺癌[1]。越来越多的观点认为,转移是肺癌患者死亡的主要原因[2],而血管生成又是肺癌转移必不可少的重要环节,了解肺癌转移的血管生成的具体机制,并应用相关技术和分析方法,对找到抑制肿瘤血管的合适靶点,从而开发出有效的肺癌治疗方法和提高患者的生存时间，具有十分重要的意义。
作者 刘贤忠 张丽婷 童卫泉 王帅 徐志波 陈芳
机构地区 浙江中医药大学第一临床医学院
出处 《现代实用医学》 2015年第1期134-136,共3页 Modern Practical Medicine
基金 浙江省科技厅钱江人才计划(2012R10063)
关键词 肺癌转移 血管生成 肿瘤血管 肺癌治疗 血管内皮细胞 细胞外基质 生存时 VEGFR 基质金属蛋白酶 定向移动
分类号 R734.2 [医药卫生—肿瘤]
作者简介 通信作者：陈芳，Email：funchen@163．com
  • 相关文献

参考文献2

二级参考文献11

  • 1宋作庆,徐萧洪,韦森,陈军,周乃康.肝素酶在非小细胞肺癌中的表达及其临床意义[J].中国肺癌杂志,2008,11(6):798-801. 被引量：6
  • 2田辉,刘贤锡,王善政.肺癌组织中乙酰肝素酶与血管内皮生长因子-C的表达[J].中华外科杂志,2004,42(16):976-979. 被引量：9
  • 3Chamber AF, Matrisian LM. Changing views of matrix metalloproteinase in metastasis [ J ]. J Natl Cancer Inst, 1997, 89(7): 1260 -1265.
  • 4Rahman MA, Dhar SK, Yamaguchi E, et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver[ J]. Clin Cancer Res, 2001,46(5) :1325 -1332.
  • 5Kraiem Z, Korem S. Matrix metalloproteinases and thyroid[J]. Thyroid, 2000,10:1061 - 1069.
  • 6Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease [ J ].Biological Chemistry Hoppe Seyler, 1995,376(6) :345 -355.
  • 7Thomas P, Khokha R, Shepherd FA, et al. Differential expression of MMPs and their inhibitors in non-small cell lung cancer[J]. J Pahol, 2000, 190(2): 150-156.
  • 8Suzuki M, Iizasa T, Fujisawa T, et al. Expression of matrix etalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer [ J ]. Invasion Metastasis,1998 -1999, 18(3) :134 -141.
  • 9Maeta H, Ohgi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase I and 2 in papillary thyroid arcinomas [ J ]. Virchows Arch,2001,438:121 - 128.
  • 10Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increase metastatic potenfal [J].Proc Natl Acad Sci USA, 1997, 4:3336 -3340.

共引文献11

同被引文献41

  • 1SANDLER A, YI J, DAHLBERG S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer [J]. J Thorac Oncol, 2010, 5(9): 1416-1423.
  • 2NIHO S, KUNITOH H, NOKIHARA H, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer [J]. Lung Cancer, 2012, 76(3): 362-367.
  • 3BRAHMER J R, DAHLBERG S E, GRAY R J, et al. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599 [J]. J Thorac Oncol, 2011, 6(1): 103-108.
  • 4JOHNSON D H, FEHRENBACHER L, NOVOTNY W F, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [J]. J Clin Oncol, 2004, 22(11): 2184-2191.
  • 5LIU K J, DING L Y, WU H Y. Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer [J]. Tumor Biol, 2015, 36(3): 1323-1327.
  • 6MORO-SIBILOT D, SMIT E, DE CASTRO CARPENO J, et al. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study [J]. Lung Cancer, 2015, 88(2): 215-222.
  • 7TAKEDA M, SETO T, HAYASHI H, et al. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial [C]//ASCO Annual Meeting Proceedings. Chicago, USA: Journal of Clinical Oncology, 2015: 8056.
  • 8HATTORI Y, SATOUCHI M, SHIMADA T, et al. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109) [J]. Lung Cancer, 2015, 87(2): 136-140.
  • 9MASAGO K, FUJIMOTO D, FUJITA S, et al. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer [J]. Mol clin oncol, 2015, 3(2): 415-419.
  • 10LIAO B C, SHAO Y Y, CHEN H M, et al. Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma [J]. Clin Lung Cancer, 2015, 16(2): 137-143.

引证文献4

二级引证文献33

现代实用医学
2015年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部